MOVING LIFE SCIENCE INNOVATIONS

FROM DISCOVERY TO DEVELOPMENT TO DELIVERY

OUR VISION OF THE FUTURE: Arizona is a top-ten life science state.

OUR MISSION: AZBio supports the needs of Arizona’s growing life science ecosystem.

OUR MEMBERS: AZBio Members make an impact. They discover, develop and deliver health innovations including medicines, medical devices, diagnostics, and a wide range of health technologies. Our members also include economic development partners, educators, investors, leading business and philanthropic organizations, and patient advocacy organizations. AZBio Members employ over 365,000 Arizonans who are working together to make life better for people in Arizona and around the world.

Our industry sector generated over $43.64 billion in Economic Impact in 2023.

That's up over 88% from 2016 and growing at a Compound Annual Growth Rate of 9.5%.

Arizona’s bioscience industry (not including our hospitals) employed 40,399 in 2023 across 3,652 state business establishments, representing a rapid 24.6 percent increase in employment since 2019 and placing the state among the leaders in employment growth. The average wage in the bioscience industry was $102,161—53 percent higher than the state’s private sector average. View More of Arizona's Bioscience Industry Data

A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on growing Arizona’s bioscience industry.

AZBio Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector. As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.

AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations.

Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.

NuvOx and FYR Bio Announce NCI Funding for Liquid Biopsy Collaboration Supporting NuvOx’s Phase IIb Glioblastoma Trial

Tucson, AZ – September 26, 2025 – NuvOx Therapeutics, Inc. (“NuvOx”) and FYR Bio (“FYR”) today announced a collaboration pairing NuvOx’s Phase IIb glioblastoma trial of NanO₂ with FYR’s EV-based liquid-biopsy expertise to provide additional biomarker insights that support clinical development, through an NCI (a division of NIH) grant “Liquid Biopsy in Glioblastoma Treated with […]

CND Life Sciences is Granted FDA Breakthrough Device Designation for Its Skin Biopsy-Based Syn-One Test®

SCOTTSDALE, AZ, October 7, 2025 – CND Life Sciences, Inc. (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for the company’s Syn-One Test® for aiding the diagnosis of synucleinopathies in patients aged 40 years and older […]

The Journey of a Plasma Donation

Plasma Donors hold the missing puzzle piece for those who rely on plasma-derived therapies. October is Plasma Awareness Month, an opportunity for CSL to raise awareness about the importance and need for plasma donations to manufacture life-saving therapies.

Amgen Makes Repatha® Available Through AMGENNOW, A Direct-to-Patient Program in the U.S.

Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price THOUSAND OAKS, Calif. Oct. 6, 2025 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart […]